8 Results

People

  1. Palomba
    Palomba
  2. Batlevi
    Batlevi
  3. Sauter
    Sauter
  4. Younes
    Younes
  5. Caron
    Caron
  6. Hamlin
    Hamlin
  7. Horwitz
    Horwitz
  8. Intlekofer
    Intlekofer
  9. Kumar
    Kumar
  10. Moskowitz
    Moskowitz

Groups

  1. Center for Hematologic Malignancies (8)
  2. Department of Medicine (8)
  3. GSK Faculty (8)
  4. Hematologic Malignancies Research (8)
  5. Hematologic Malignancies, Division of (8)
  6. Lymphoma (8)
  7. Population Sciences Research Program (8)
  8. Solid Tumor Oncology Division (8)
  9. Survivorship Research (8)
  10. Bone Marrow Transplant (7)
  1. "Center for Hematologic Malignancies"
  2. "Hematologic Malignancies Research"
  3. "Population Sciences Research Program"
  4. "Solid Tumor Oncology Division"
  5. "Maria Palomba"
Formats
  1. Meeting Abstract (8)
Groups
  1. Center for Hematologic Malignancies (8)
  2. Department of Medicine (8)
  3. GSK Faculty (8)
  4. Hematologic Malignancies Research (8)
  5. Hematologic Malignancies, Division of (8)
  6. Lymphoma (8)

More Groups

People
  1. Maria Palomba (8)
  2. Anas Younes (7)
  3. Connie Batlevi (7)
  4. Craig Sauter (7)
  5. Alison Moskowitz (5)
  6. Andrew Intlekofer (5)

More People

Years
  1. 2023 (1)
  2. 2019 (2)
  3. 2018 (1)
  4. 2017 (2)
  5. 2016 (2)
Publications
  1. Blood (4)
  2. Hematological Oncology (2)
  3. Biology of Blood and Marrow Transplantation (1)
  4. Value in Health (1)
Publishers
  1. American Society of Hematology (4)
  2. Wiley Blackwell (2)
  3. Elsevier Inc. (1)
  4. Elsevier Science, Inc. (1)

Results (8)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase 2 trial of nivolumab plus adriamycin, vinblastine, dacarbazine (N‐AVD) as frontline therapy in older adults with Hodgkin lymphoma
    Meeting Abstract

    Torka, P.; Feldman, T.; Savage, K.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Thirty day resource utilization after chimeric antigen receptor (CAR) T cell infusion for hematologic malignancies
    Meeting Abstract

    Shah, G. L.; Park, J.; Sauter, C. S.; Duck, E.; Halton, E.; Batlevi, C. W.; Palomba, M. L.; Younes, A.; Geyer, M. B.; Smith, E.; more...
    Biology of Blood and Marrow Transplantation (2019)

    Fulltext@MSK | Save
  • Resource utilization within 30 days of car T cells for hematologic malignancies
    Meeting Abstract

    Shah, G.; Park, J.; Sauter, C.; Duck, E.; Halton, E.; Batlevi, C.; Palomba, M. L.; Younes, A.; Geyer, M.; Smith, E.; more...
    Value in Health (2019)

    Fulltext@MSK | Save
  • Resource utilization early after chimeric antigen receptor (CAR) T cell infusion for hematologic malignancies
    Meeting Abstract

    Shah, G. L.; Park, J. H.; Sauter, C. S.; Duck, E.; Halton, E.; Palomba, M. L.; Batlevi, C. L.; Younes, A.; Geyer, M. B.; Smith, E. L.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Impact of PET staging of follicular lymphoma on treatment outcomes and prognosis
    Meeting Abstract

    Alperovich, A.; Batlevi, C. L.; Intlekofer, A. M.; Moskowitz, C. H.; Horwitz, S. M.; Zelenetz, A. D.; Palomba, M. L.; Moskowitz, A. J.; Gerecitano, J.; Hamlin, P. A.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Time from prognosis to 2nd treatment is a promising surrogate for overall survival in patients with advanced stage follicular lymphoma
    Meeting Abstract

    Soumerai, J. D.; Ni, A.; Batlevi, C.; Alperovich, A.; Bantilan, K. S.; Palomba, M.; Gerecitano, J. F.; Noy, A.; Hamlin, P.; Moskowitz, C. H.; more...
    Hematological Oncology (2017)

    Fulltext@MSK | Save
  • Outcomes of follicular lymphoma patients by dynamic FLIPI at diagnosis and initial treatment in the post-rituximab era
    Meeting Abstract

    Batlevi, C.; Alperovich, A.; Smith, K.; Ying, Z.; Soumerai, J. D.; Copeland, A. R.; Joffe, E.; Caron, P.; Drullinsky, P.; Gerecitano, J. F.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Benchmark of progression free survival for multiple lines of therapy in follicular lymphoma treated in the rituximab era
    Meeting Abstract

    Alperovich, A.; Batlevi, C.; Smith, K.; Ying, Z.; Soumerai, J. D.; Copeland, A. R.; Joffe, E.; Caron, P.; Drullinsky, P.; Gerecitano, J. F.; more...
    Blood (2016)

    Fulltext@MSK | Save